肝炎治療薬市場：タイプ別、薬剤クラス別、流通チャネル別-2025-2030年の世界予測

肝炎治療薬市場は、2023年に291億9,000万米ドルと評価され、2024年には307億6,000万米ドルに達すると予測され、CAGR 4.11％で成長し、2030年には387億1,000万米ドルに達すると予測されています。

肝炎治療薬市場には、主にA型、B型、C型、D型、E型肝炎など、さまざまな肝炎の管理と治癒を目的とした治療法の開拓、流通、応用が含まれます。その範囲には、抗ウイルス薬、ワクチン、免疫系調整剤、これらのウイルスによる肝臓感染症との闘いに不可欠な支持療法が含まれます。肝炎治療薬の必要性は、肝硬変やがんのような重篤な合併症を引き起こすことが多く、効果的な治療が必要とされる肝疾患の世界の重荷から生じています。肝炎治療薬は、病院、診療所、専門治療センターなど幅広い用途で使用されており、最終用途は、世界中で肝炎ウイルスが広く蔓延していることから、先進地域と発展途上地域の両方を対象としています。

市場開拓は、肝炎に対する意識の高まり、有効性の高い抗ウイルス薬の開発、予防接種プログラムの普及に向けた政府の取り組み、診断ツールの増加といった要因に大きく影響されます。また、薬剤製剤やドラッグデリバリー・システムにおける技術的進歩も、市場の需要を促進する上で極めて重要です。しかし、特に低所得地域における高額な治療費、厳しい規制要件、ウイルス変異の出現といった制約が、市場拡大の課題となっています。より多くのウイルス株をカバーするワクチンの研究拡大、低資源環境に適した費用対効果の高い治療法の開発、より良い管理と患者のコンプライアンスを実現するためのデジタルヘルス技術の活用などに機会が存在します。革新的な治療分野としては、新規治療クラス、個人の遺伝子プロファイルに基づいて治療を調整する個別化医療アプローチ、アドヒアランスと転帰を改善する長時間作用型注射剤の開発などがあります。

こうしたビジネスチャンスを生かすため、企業は研究機関との戦略的提携、研究開発投資の強化、有病率が高いにもかかわらず臨床ニーズが満たされていない未開拓地域への市場参入に注力すべきです。市場情勢はダイナミックで、製薬大手やバイオテクノロジー企業が医薬品開発のブレークスルーを通じて足場を固めようと競争が激化しており、厳しい情勢であると同時にイノベーションのための肥沃な土壌となっています。

市場力学：急速に進化する肝炎治療薬市場の主要市場インサイトを公開

肝炎治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 老年人口における肝炎負担の増加
  • 肝炎治療に対する政府の積極的な取り組み
  • ヘルスケアインフラの拡大
• 市場抑制要因
  • 肝炎治療薬と診断にかかるコストの高さ
• 市場機会
  • 肝炎撲滅に向けたイノベーションのイントロダクション
  • 肝炎治療薬の継続的な研究開発活動
• 市場の課題
  • 肝炎治療薬に付随する副作用

ポーターのファイブフォース：肝炎治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、肝炎治療薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肝炎治療薬市場における外部からの影響の把握

外部マクロ環境要因は、肝炎治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析肝炎治療薬市場における競合情勢の把握

肝炎治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス肝炎治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肝炎治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨肝炎治療薬市場における成功への道筋を描く

肝炎治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者人口における肝炎の負担増加
    • 肝炎治療に対する政府の好ましい取り組み
    • ヘルスケアインフラの拡大
  • 抑制要因
    • 肝炎治療薬と診断のコストが高い
  • 機会
    • 肝炎撲滅に向けたイノベーションのイントロダクション
    • 肝炎治療薬の進行中の研究開発活動
  • 課題
    • 肝炎治療薬に関連する副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肝炎治療薬市場：タイプ別

• A型肝炎
• B型肝炎
• C型肝炎

第7章 肝炎治療薬市場薬剤クラス別

• 免疫調節剤
• 経口抗ウイルス薬

第8章 肝炎治療薬市場：流通チャネル別

• ドラッグストア
• オンライン
• 薬局

第9章 南北アメリカの肝炎治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の肝炎治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの肝炎治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AbbVie Inc.
• Avantor Inc.
• Bio-Rad Laboratories Inc.
• bioMerieux SA
• Bristol-Myers Squibb Company
• DiaSorin S.p.A.
• F. Hoffmann-La Roche AG
• FUJIREBIO Inc.
• Gilead Sciences, Inc.
• Grifols S.A.
• Johnson & Johnson Services Inc
• Merck & Co., Inc.
• Ortho Clinical Diagnostics
• Quest Diagnostics Incorporated

LIST OF FIGURES

• FIGURE 1. HEPATITIS THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. HEPATITIS THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HEPATITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HEPATITIS THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY IMMUNE MODULATOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ORAL ANTIVIRAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HEPATITIS THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. CANADA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES HEPATITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. CHINA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. INDIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. ITALY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. POLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 117. QATAR HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM HEPATITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. HEPATITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. HEPATITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Hepatitis Therapeutics Market was valued at USD 29.19 billion in 2023, expected to reach USD 30.76 billion in 2024, and is projected to grow at a CAGR of 4.11%, to USD 38.71 billion by 2030.

The hepatitis therapeutics market encompasses the development, distribution, and application of medical treatments aimed at managing and curing various forms of hepatitis, primarily hepatitis A, B, C, D, and E. Its scope includes antiviral medications, vaccines, immune system modulators, and supportive care options vital in combating liver infections caused by these viruses. The necessity for hepatitis therapeutics arises from the global burden of liver diseases, which often lead to severe complications like liver cirrhosis and cancer, necessitating effective treatments. Hepatitis therapies find applications across hospitals, clinics, and specialized treatment centers, with end-use targeting both developed and developing regions due to the widespread prevalence of hepatitis strains worldwide.

Market growth is significantly influenced by factors such as rising awareness of hepatitis conditions, the development of highly effective antiviral drugs, governmental initiatives for widespread immunization programs, and the increased availability of diagnostic tools. Technological advancements in drug formulation and delivery systems are also pivotal in driving market demand. However, limitations such as the high cost of treatment, especially in low-income regions, stringent regulatory requirements, and the emergence of virus mutations challenge market expansion. Opportunities exist in expanding research on vaccines to cover more viral strains, developing cost-effective therapies suitable for low-resource settings, and leveraging digital health technologies for better management and patient compliance. Innovative areas for exploration include novel therapeutic classes, personalized medicine approaches that tailor treatment based on individual genetic profiles, and development of long-acting injectables for better adherence and outcomes.

To exploit these opportunities, businesses should focus on strategic collaborations with research institutions, enhanced investment in R&D, and pursuing market entry into untapped regions with high disease prevalence yet unmet clinical needs. The nature of the market is dynamic, with increasing competition among pharmaceutical giants and biotech firms striving to secure a foothold through breakthroughs in drug development, creating both a challenging landscape and a fertile ground for innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hepatitis Therapeutics Market

The Hepatitis Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising burden of hepatitis in geriatric population
  • Favorable government initiatives for hepatitis treatment
  • Expanding healthcare infrastructure
• Market Restraints
  • High cost of hepatitis therapeutics and diagnosis
• Market Opportunities
  • Introduction to innovations in hepatitis elimination
  • Ongoing research and development activities for hepatitis therapeutics
• Market Challenges
  • Associated side effects of hepatitis therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Hepatitis Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hepatitis Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hepatitis Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hepatitis Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hepatitis Therapeutics Market

A detailed market share analysis in the Hepatitis Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hepatitis Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hepatitis Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hepatitis Therapeutics Market

A strategic analysis of the Hepatitis Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hepatitis Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Avantor Inc., Bio-Rad Laboratories Inc., bioMerieux SA, Bristol-Myers Squibb Company, DiaSorin S.p.A., F. Hoffmann-La Roche AG, FUJIREBIO Inc., Gilead Sciences, Inc., Grifols S.A., Johnson & Johnson Services Inc, Merck & Co., Inc., Ortho Clinical Diagnostics, and Quest Diagnostics Incorporated.

Market Segmentation & Coverage

This research report categorizes the Hepatitis Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Hepatitis A, Hepatitis B, and Hepatitis C.
• Based on Drug Class, market is studied across Immune Modulator and Oral Antiviral.
• Based on Distribution Channel, market is studied across Drug Stores, Online, and Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising burden of hepatitis in geriatric population
    • 5.1.1.2. Favorable government initiatives for hepatitis treatment
    • 5.1.1.3. Expanding healthcare infrastructure
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of hepatitis therapeutics and diagnosis
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction to innovations in hepatitis elimination
    • 5.1.3.2. Ongoing research and development activities for hepatitis therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Associated side effects of hepatitis therapeutics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hepatitis Therapeutics Market, by Type

• 6.1. Introduction
• 6.2. Hepatitis A
• 6.3. Hepatitis B
• 6.4. Hepatitis C

7. Hepatitis Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Immune Modulator
• 7.3. Oral Antiviral

8. Hepatitis Therapeutics Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Drug Stores
• 8.3. Online
• 8.4. Pharmacies

9. Americas Hepatitis Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Hepatitis Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Hepatitis Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AbbVie Inc.
• 3. Avantor Inc.
• 4. Bio-Rad Laboratories Inc.
• 5. bioMerieux SA
• 6. Bristol-Myers Squibb Company
• 7. DiaSorin S.p.A.
• 8. F. Hoffmann-La Roche AG
• 9. FUJIREBIO Inc.
• 10. Gilead Sciences, Inc.
• 11. Grifols S.A.
• 12. Johnson & Johnson Services Inc
• 13. Merck & Co., Inc.
• 14. Ortho Clinical Diagnostics
• 15. Quest Diagnostics Incorporated